Zasocitinib (TAK-279) - (LATITUDE PsO)

July 16, 2026: Takeda (TAK) presented secondary endpoint data at the 2026 American Academy of Dermatology (AAD) Innovation Academy from two pivotal Phase 3 LATITUDE plaque psoriasis trials (LATITUDE PsO 3001/3002; NCT06088043/NCT06108544) evaluating once-daily oral TYK2 inhibitor zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis versus placebo and apremilast.

High-impact site outcomes at week 16:

• Scalp psoriasis: 77% and 74% achieved scalp-specific PGA (ssPGA) 0/1 vs placebo (7%/13%; p<0.001) and vs apremilast (42%/30%; p<0.001).
• Palmoplantar psoriasis: ~70% achieved hands/feet-specific PGA (hfPGA) 0/1 (71%/69%) vs placebo (22%/10%) and apremilast (44%/43) (numerically higher).
• Nail psoriasis: statistically significant improvement in NAPSI vs placebo at week 16 (p<0.001). Responses were sustained through week 24. Most common AEs through week 24 were upper respiratory tract infection, nasopharyngitis, and acne; no new safety signals were identified.

Next steps: Takeda plans to begin NDA submissions for plaque psoriasis in the U.S. and other regions starting this fiscal year. Zasocitinib is also in Phase 3 for psoriatic arthritis and Phase 2 for Crohn’s disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa.